Gemcitabine

Generic Name: Gemcitabine

Brand Names: Gemzar

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₁F_₂N_₃O_₄

CAS Number: 95058-81-4

Unique Ingredient Identifier: B76N6SBZ8R

Background: Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...

Indication: Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.

In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...

Associated Conditions: Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Gemcitabine
Drug: Epirubicin
Drug: Albumin-bound Paclitaxel

First Posted Date: 2005-09-19

Last Posted Date: 2021-11-23

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 123

Registration Number: NCT00193206

Locations: 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

and more 10 locations

A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Gemcitabine
Drug: avastin
Drug: 5FU/folinic acid
Drug: oxaliplatin

First Posted Date: 2005-09-19

Last Posted Date: 2011-02-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 84

Registration Number: NCT00192075

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milwaukee, Wisconsin, United States

Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: gemcitabine
Drug: cisplatin
Radiation: radiation

First Posted Date: 2005-09-19

Last Posted Date: 2010-12-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 49

Registration Number: NCT00192036

Locations: 🇧🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Turnhout, Belgium

Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Docetaxel
Drug: Gemcitabine
Drug: Carboplatin
Radiation: Radiation

First Posted Date: 2005-09-19

Last Posted Date: 2022-03-03

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 75

Registration Number: NCT00193427

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Gemcitabine
Drug: docetaxel

First Posted Date: 2005-09-19

Last Posted Date: 2019-09-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 237

Registration Number: NCT00191243

Locations: 🇫🇮
For additional information regarding investigative sites for this trial, contact 1-877-CT-LILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Turku, Finland

Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab
Drug: Gemcitabine

First Posted Date: 2005-09-19

Last Posted Date: 2014-03-12

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 41

Registration Number: NCT00193063

Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Gemcitabine
Drug: Epirubicin
Drug: Docetaxel

First Posted Date: 2005-09-19

Last Posted Date: 2021-10-26

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 110

Registration Number: NCT00193050

Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: gemcitabine

First Posted Date: 2005-09-19

Last Posted Date: 2010-03-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 68

Registration Number: NCT00191269

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan

Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: gemcitabine
Drug: paclitaxel
Drug: carboplatin
Drug: cisplatin

First Posted Date: 2005-09-19

Last Posted Date: 2010-03-02

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 147

Registration Number: NCT00191854

Locations: 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kayseri, Turkey

Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: gemcitabine
Drug: cisplatin
Drug: docetaxel
Drug: etoposide
Radiation: radiation therapy

First Posted Date: 2005-09-19

Last Posted Date: 2010-02-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 64

Registration Number: NCT00191139

Locations: 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph, Suwon-City, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy